FY2025 Earnings Estimate for LLY Issued By Cantor Fitzgerald

Eli Lilly and Company (NYSE:LLY) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for Eli Lilly and Company in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen expects that the company will earn $22.29 per share for the year. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $12.98 per share.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same period in the previous year, the company earned $0.10 EPS. Eli Lilly and Company’s quarterly revenue was up 20.4% on a year-over-year basis.

Several other equities analysts have also commented on LLY. Bank of America reiterated a “buy” rating and set a $997.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday. Truist Financial increased their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a report on Thursday, October 10th. Finally, Sanford C. Bernstein began coverage on shares of Eli Lilly and Company in a research note on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price target for the company. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,002.22.

Eli Lilly and Company Trading Up 1.6 %

NYSE LLY opened at $766.00 on Wednesday. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The stock’s 50-day simple moving average is $776.31 and its two-hundred day simple moving average is $850.93. Eli Lilly and Company has a twelve month low of $624.68 and a twelve month high of $972.53. The company has a market capitalization of $727.18 billion, a price-to-earnings ratio of 82.81, a PEG ratio of 1.56 and a beta of 0.41.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, February 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.78%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s payout ratio is currently 56.22%.

Eli Lilly and Company announced that its board has approved a share repurchase program on Monday, December 9th that authorizes the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.13% of the stock is owned by insiders.

Institutional Investors Weigh In On Eli Lilly and Company

Several hedge funds have recently made changes to their positions in the company. Heck Capital Advisors LLC purchased a new position in Eli Lilly and Company during the fourth quarter valued at $2,042,000. Caprock Group LLC lifted its position in Eli Lilly and Company by 3.9% during the 4th quarter. Caprock Group LLC now owns 70,425 shares of the company’s stock valued at $54,369,000 after acquiring an additional 2,666 shares during the period. TCI Wealth Advisors Inc. boosted its stake in Eli Lilly and Company by 0.4% during the fourth quarter. TCI Wealth Advisors Inc. now owns 8,227 shares of the company’s stock worth $6,351,000 after acquiring an additional 31 shares in the last quarter. Alta Wealth Advisors LLC grew its holdings in Eli Lilly and Company by 0.5% in the fourth quarter. Alta Wealth Advisors LLC now owns 3,061 shares of the company’s stock worth $2,363,000 after purchasing an additional 16 shares during the period. Finally, Keudell Morrison Wealth Management increased its stake in shares of Eli Lilly and Company by 6.0% during the fourth quarter. Keudell Morrison Wealth Management now owns 5,308 shares of the company’s stock valued at $4,098,000 after purchasing an additional 302 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.